Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,974 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.
McGarvey L, Niewoehner D, Magder S, Sachs P, Tetzlaff K, Hamilton A, Korducki L, Bothner U, Vogelmeier C, Koch A, Ferguson GT. McGarvey L, et al. Among authors: koch a. COPD. 2015;12(5):484-93. doi: 10.3109/15412555.2014.991864. Epub 2015 Feb 18. COPD. 2015. PMID: 25692310 Free PMC article. Clinical Trial.
β-Blockers in COPD: A Cohort Study From the TONADO Research Program.
Maltais F, Buhl R, Koch A, Amatto VC, Reid J, Grönke L, Bothner U, Voß F, McGarvey L, Ferguson GT. Maltais F, et al. Among authors: koch a. Chest. 2018 Jun;153(6):1315-1325. doi: 10.1016/j.chest.2018.01.008. Epub 2018 Jan 31. Chest. 2018. PMID: 29355547 Free article. Clinical Trial.
Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET.
Trudzinski FC, Jörres RA, Alter P, Walter J, Watz H, Koch A, John M, Lommatzsch M, Vogelmeier CF, Kauczor HU, Welte T, Behr J, Tufman A, Bals R, Herth FJF, Kahnert K; COSYCONET Study Group. Trudzinski FC, et al. Among authors: koch a. Sci Rep. 2022 May 24;12(1):8790. doi: 10.1038/s41598-022-12828-8. Sci Rep. 2022. PMID: 35610473 Free PMC article.
Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P. Koch A, et al. Int J Chron Obstruct Pulmon Dis. 2014 Jul 5;9:697-714. doi: 10.2147/COPD.S62502. eCollection 2014. Int J Chron Obstruct Pulmon Dis. 2014. PMID: 25045258 Free PMC article. Clinical Trial.
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Rabe KF, et al. N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24. N Engl J Med. 2020. PMID: 32579807 Clinical Trial.
Asthma features in severe COPD: Identifying treatable traits.
Matthes S, Stadler J, Barton J, Leuschner G, Munker D, Arnold P, Villena-Hermoza H, Frankenberger M, Probst P, Koch A, Kneidinger N, Milger K, Behr J, Neurohr C. Matthes S, et al. Among authors: koch a. Respir Med. 2018 Dec;145:89-94. doi: 10.1016/j.rmed.2018.10.027. Epub 2018 Oct 26. Respir Med. 2018. PMID: 30509722 Free article.
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A; RELIEF investigators. Behr J, et al. Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30. Lancet Respir Med. 2021. PMID: 33798455 Clinical Trial.
Activation of immune cell proteasomes in peripheral blood of smokers and COPD patients: implications for therapy.
Kammerl IE, Hardy S, Flexeder C, Urmann A, Peierl J, Wang Y, Vosyka O, Frankenberger M, Milger K, Behr J, Koch A, Merl-Pham J, Hauck SM, Pilette C, Schulz H, Meiners S. Kammerl IE, et al. Among authors: koch a. Eur Respir J. 2022 Mar 3;59(3):2101798. doi: 10.1183/13993003.01798-2021. Print 2022 Mar. Eur Respir J. 2022. PMID: 34561290 Free PMC article.
2,974 results